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MDA-MB-231 cells. We thus assessed whether CIP2A expression is associated with sensitivity to
doxorubicin. MDA-MB-231 cells showed an increase in CIP2A expression after treatment with doxo-
rubicin, while MCF-7 cells showed a decrease in CIP2A expression. The overexpression of CIP2A in
MCF-7 cells overcame the inhibition of cell proliferation in response to doxorubicin treatment.
CIP2A expression was not affected by wild-type or mutant p53. However, mutant p53 blocked doxo-
rubicin-mediated CIP2A down-regulation in HCT116 cells. As a regulation mechanism of doxorubi-
cin-mediated CIP2A expression, we showed that phosphorylated Akt was involved in the
suppression of CIP2A expression.
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The abnormal function of oncogenes and tumor-suppressor
genes leads to cancer, and many such genes are being identiﬁed.
One of these genes, the cancerous inhibitor of protein phosphatase
2A (CIP2A), is highly expressed in head and neck squamous cell
carcinoma, colon cancer, gastric cancer and breast cancer [1–4].
CIP2A stabilizes the c-Myc protein by inhibiting its degradation
mediated by protein phosphatase 2A (PP2A) in cancer cells, and
it is associated with malignant growth and aggressiveness [1,2].
The proto-oncogene c-Myc has been linked to a diverse range of
cellular functions, such as cell cycle regulation, proliferation, and
growth. Therefore, aberrant c-Myc signaling promotes cell trans-
formation and tumor progression. Phosphorylation at serine 62
(S62) by extracellular-regulated kinase 1/2 (ERK1/2) stabilizes c-
Myc [5,6]. Threonine 58 (T58) is phosphorylated by glycogen syn-
thase kinase (GSK-3b) only after S62 is phosphorylated, and only
T58 phosphorylation targets c-Myc for degradation [7]. PP2A
dephosphorylates c-Myc at S62, which leads to the destabilization
of c-Myc [8]. CIP2A blocks this PP2A-mediated c-Myc dephospho-
rylation pathway [9].
Doxorubicin, an anthracycline, is commonly used to treat many
cancers, including breast, Hodgkin’s lymphoma, bladder, andchemical Societies. Published by E
ung.ac.kr (Y. Yang).stomach cancers; but a major problem is the occurrence of drug
resistance. Doxorubicin induces increased expression of the apop-
totic CD95 receptor, thus, inducing apoptosis, and CD95 receptor
expression is regulated by p53 [10,11]. These results suggest that
tumor-suppressor protein p53 would affect the cytotoxicity of
doxorubicin [12,13]. It has also been reported that a lack of p53
leads to doxorubicin resistance due to a reduced induction of apop-
totic cell death [14]. However, a detailed mechanism remains to be
elucidated. In this study, we measured the effect of CIP2A on the
doxorubicin-mediated inhibition of cell proliferation because
CIP2A increases the proliferation of several cancer cells. Our ﬁnd-
ings uncover the mechanisms of CIP2A regulation by doxorubicin
and CIP2A-mediated doxorubicin resistance.2. Materials and methods
2.1. Reagents and plasmids
Plasmids encoding four p53 mutants (MDA-MB-231 (R280K),
MDA-MB-468 (R273H), BT549 (R249S), and R175H) were kindly
obtained from Dr. BernardW. Futscher at the University of Arizona,
USA [15]. The plasmid encoding CIP2A was a kind gift of Dr. Jukka
Westermarck at the University of Turku and Abo Akademi Univer-
sity, Finland. Plasmids expressing dominant negative Akt (DN-Akt),
dominant negative PI3K (DN-PI3K), constitutively active Aktlsevier B.V. All rights reserved.
Fig. 1. Effect of CIP2A on proliferation of MDA-MB-231 cells. (A) Cells were
transfected with a CIP2A expression plasmid, and total RNA was isolated 24 h after
transfection and then subjected to RT-PCR analysis or total protein was isolated and
then followed by subjected to Western blot analysis. (B) Cells were transfected with
a CIP2A expression plasmid, and then the number of viable cells was counted by
using a hemoatocytometer 24 h after transfection. (C) Cells were transfected with a
CIP2A siRNA, and total protein was isolated 24 h after transfection and then
followed by subjected to immunoblot analysis. (D) Cells were transfected with a
CIP2A siRNA, and then the number of viable cells was counted by using a
hemoatocytometer 24 h after transfection. Data shown are representative of three
independent experiments performed in triplicates. All values are represented as the
means ± standard deviation. ⁄P < 0.05, ⁄⁄P < 0.01 versus control.
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from Dr. Jeong-Hyung Lee at Kangwon National University, Korea.
Doxorubicin was purchased from Calbiochem (Darmstadt, Ger-
many). Cisplatin, cyclophosphamide, and paclitaxel were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). SB203580,
SP600125, U0126, and LY294002 were purchased from Biomol Re-
search Laboratories Inc. (Plymouth Meeting, PA, USA).
2.2. Cell culture
Human breast cancer cell lines MDA-MB-231 and MCF-7 were
purchased from the American Type Culture Collection. MDA-MB-
231 cells, MCF-7 cells, the human colon cancer cell line HCT116,
and p53-deﬁcient HCT116 cells [16] were cultured in Dullbecco’s
Modiﬁed Eagle’s Medium (DMEM) (WelGENE, Daegu, Korea) sup-
plemented with 10% fetal bovine serum (HyClone, South Logan,
USA) at 37 C in a humidiﬁed 5% CO2 incubator.
2.3. Proliferation assay
For the proliferation assay, cells transfected with the CIP2A
expression plasmid or CIP2A siRNA [4] were seeded in 12-well
plates at a density of 3  105 cells per well and treated with the
indicated concentration of doxorubicin. The number of viable
cells was determined by counting cells 24 h after the doxorubicin
treatment, and dead cells were excluded using trypan blue
staining.
2.4. Immunoblot analysis
Total cell lysates were prepared 24 h after transfection with
mutant or wild-type p53 or the CIP2A expression plasmid or CIP2A
siRNA, mixed with 5 sodium dodecyl sulfate (SDS) sample buffer,
and then sonicated for 15 s. The sonicated samples were heated at
95 C for 5 min and separated electrophoretically on a 12% SDS–
polyacrylamide gel. Subsequently, proteins were transferred onto
a 0.45-lm nitrocellulose membrane (GE Healthcare, England, UK)
for 2 h. The membrane was incubated with antibodies speciﬁc for
CIP2A (Santa Cruz Biotechnology, CA, USA; cat. no. sc-80659),
p53 (Santa Cruz Biotechnology, CA, USA; cat. no. sc-6243), phos-
pho-Akt (Cell Signaling Technology Inc., MA, USA; cat. no. 9275S),
and Akt (Santa Cruz Biotechnology, CA, USA; cat. no. sc-1619).
The membrane was then incubated with anti-rabbit or anti-mouse
IgG secondary antibody conjugated to horseradish peroxidase (As-
say Design, MI, USA) at room temperature for 2 h. The proteins
were visualized using an enhanced chemiluminescent substrate
(Thermo Fisher Scientiﬁc, UT, USA) and analyzed using a LAS3000
luminescent image analyzer (Fuji Film, Tokyo, Japan).
2.5. Reverse transcription-PCR
Total cellular RNA was extracted using the RNAiso plus kit
(Takara, Shiga, Japan). A total of 3 lg of RNA was transcribed with
0.5 lg of random primer using reverse transcriptase (Fermentes,
Ontario, Canada) at 42 C, for 1 h. The followings primers were
used for ampliﬁcation: CIP2A, forward primer (50-GGGAATTCCCT-
GATTCCTCTTCA-30) and reverse primer (50-CCCTCGAGCTAGAAG-
CTTACTTCCAT-30), and b-actin, forward primer (50-GTGGGGC-
GCCCCCAGGCACCA-30) and reverse primer (50-CTCCTTAATGT-
CACGCACGAT-30). PCR was performed using 30 cycles of ampliﬁca-
tion. Each ampliﬁcation cycle consisted of 30 s of denaturation at
94 C, 30 s of annealing at 55 C, and 30 s of extension at 72 C,
and PCR was performed using a PTC-100 from MJ Research Inc.
(Waltham, MA, USA). The reaction mixtures of PCR were run at
1% agarose gel and photographed.3. Results
3.1. Effect of CIP2A expression on the doxorubicin-mediated inhibition
of breast cancer cell proliferation
Previously, it was shown that MDA-MB-231 cells deﬁcient in
CIP2A show a signiﬁcant decrease in anchorage-independent
growth, tumor volume, and proliferation [1]. In this study, we
examined whether an increase in CIP2A expression was associated
with sensitivity against the doxorubicin-induced inhibition of cell
proliferation. MDA-MB-231 cells were ﬁrst transfected with CIP2A,
and the expression of CIP2A was conﬁrmed using RT-PCR and
immunoblot analysis (Fig. 1A). CIP2A was highly expressed at both
the mRNA and protein levels. The overexpression of CIP2A resulted
in a signiﬁcant increase in the proliferation of breast cancer cells
(Fig. 1B). To further conﬁrm this result, MDA-MB-231 cells were
transfected with CIP2A siRNA, and the expression of CIP2A was
examined using immunoblot analysis (Fig. 1C). The level of CIP2A
was markedly decreased by the CIP2A siRNA treatment and the
knock-down of CIP2A resulted in a signiﬁcant decrease in the pro-
liferation (Fig. 1D). Then, we examined whether treatment with
doxorubicin affected the expression level of CIP2A. MDA-MB-231
and MCF-7 cells were treated with doxorubicin, and the expression
level of CIP2A was determined using RT-PCR and immunoblot anal-
ysis. CIP2A expression was transcriptionally and translationally in-
creased in MDA-MB-231 cells but decreased in MCF-7 cells after
doxorubicin treatment in a dose-dependent manner (Fig. 2A). To
determine whether this difference in CIP2A expression was associ-
ated with sensitivity against the doxorubicin-induced inhibition of
cell proliferation, the cell proliferation levels of both cells were
Fig. 2. Effect of CIP2A on doxorubicin sensitivity. (A) MDA-MB-231 and MCF-7 cells were treated with 0.25, 0.5, and 1 lM concentration of doxorubicin for 24 h, and then
CIP2A and p53 levels were measured using immunoblot analysis. For RT-PCR analysis, total RNA was isolated from doxorubicin-treated cells, and the level of CIP2A level was
determined. (B) MDA-MB-231 and MCF-7 cells were treated with 0.25, 0.5, and 1 lM concentration of doxorubicin for 24 h, and then viable cells were then counted. (C) MCF-
7 cells were transfected with a CIP2A- expressing plasmid and treated with 0.25, 0.5, and 1 lM concentration of doxorubicin for 24 h, and then viable cells were then counted.
(D) MDA-MB-231 cells were transfected with CIP2A siRNA to knock-down CIP2A expression and treated with 0.25, 0.5, and 1 lM concentration of doxorubicin for 24 h, and
then viable cells were then counted. Data shown are representative of three independent experiments performed in triplicates. All values are represented as the
means ± standard deviation. ⁄P < 0.05 versus control. (E) MCF-7 cells were treated with the indicated concentration of drugs for 24 h and the level of CIP2A level was
determined using immunoblot analysis. Cyclo, cyclophosphamide; Pac, paclitaxel.
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susceptible to doxorubicin-mediated inhibition of cell proliferation
than MDA-MB-231 cells (Fig. 2B). To determine whether the
difference in sensitivity against doxorubicin was caused by the
difference in the CIP2A expression level, MCF-7 cells were transfec-
ted with CIP2A and then treated with doxorubicin. Overexpression
of CIP2A overcame the doxorubicin-mediated inhibition of cell pro-
liferation (Fig. 2C). To further conﬁrm this result, MDA-MB-231
cells were transfected with CIP2A siRNA before treatment with
doxorubicin. The reduced expression of CIP2A enhanced the doxo-
rubicin-mediated inhibition of cell proliferation (Fig. 2D). To exam-
ine whether the regulation of CIP2A expression was general to
chemotherapeutic drug, MCF-7 cells were treated with cyclophos-
phamide and paclitaxel. Both chemotherapeutic drugs did not de-
crease the expression level of CIP2A (Fig. 2E). These results imply
that the level of CIP2A expression determines sensitivity to only
doxorubicin in breast cancer cells.
3.2. Mutant p53 blocks doxorubicin-mediated CIP2A down-regulation
in HCT116 cells
Because it has previously been shown that CIP2A is more highly
expressed in breast cancer patients with a p53 mutation comparedto patients with wild-type p53 [1] and that treatment with doxo-
rubicin greatly decreased the expression level of CIP2A in MCF-7
cells containing wild-type p53 but increased the CIP2A expression
level in MDA-MB-231 cells containing only mutant p53 (Fig. 2A),
we determined the relationship between CIP2A and p53. First, to
determine whether p53 was involved in the doxorubicin-mediated
induction of CIP2A expression, HCT116 and p53-deﬁcient HCT116
cells were treated with doxorubicin. Doxorubicin decreased CIP2A
expression in HCT116 cells similar to MCF-7 cells, whereas it in-
creased CIP2A expression in p53-deﬁcient HCT116 cells in a
dose-dependent manner (Fig. 3A), similar to MDA-MB-231 cells.
Thus, to determine whether wild-type p53 was responsible for
the decrease in CIP2A expression in response to doxorubicin
treatment, p53-deﬁcient HCT116 cells were transfected with a
wild-type p53 expression plasmid followed by treatment with
doxorubicin. Doxorubicin increased CIP2A expression regardless
of the presence of wild-type p53 (Fig. 3B). These results demon-
strate that doxorubicin increases CIP2A expression through a
wild-type p53-independent pathway.
Next, to determine whether mutant p53 was involved in the in-
crease in CIP2A expression in response to doxorubicin treatment,
p53-deﬁcient HCT116 cells were transfected with mutant p53
because MDA-MB-231 cells only express mutant p53 (R280K).
Fig. 3. Effect of wild-type p53 on doxorubicin-induced CIP2A expression. (A)
HCT116 and p53-deﬁcient cells were treated with 0.25, 0.5, and 1 lM concentration
of doxorubicin. CIP2A and p53 levels were measured using immunoblot analysis
24 h after the doxorubicin treatment. (B) p53-deﬁcient HCT116 cells were
transfected with wild-type p53 and then treated with doxorubicin. CIP2A and
p53 levels were measured using immunoblot analysis 24 h after the doxorubicin
treatment.
758 Y.A. Choi et al. / FEBS Letters 585 (2011) 755–760The expression of mutant p53 did not affect the doxorubicin-med-
iated up-regulation of CIP2A expression (Fig. 4A). To determine the
effect of other types of p53 mutants on CIP2A expression, p53-deﬁ-
cient HCT116 cells were transfected with various types of mutant
p53, including R273H, R249S, and R175H. None of the mutantFig. 4. Effect of mutant p53 on doxorubicin-induced CIP2A expression. (A) p53-
deﬁcient HCT116 cells were transfected with mutant p53 (R280K) and treated with
0.25, 0.5, and 1 lM concentration of doxorubicin. CIP2A and p53 levels were
measured using immunoblot analysis 24 h after the doxorubicin treatment. (B) p53-
deﬁcient HCT116 cells were transfected with mutant p53 (R273H, R249S, R175H)
and treated with 1 lM concentration of doxorubicin. CIP2A and p53 levels were
measured using immunoblot analysis 24 h after the doxorubicin treatment. (C)
HCT116 cells were transfected with mutant p53 (R273H, R249S, R175H) and treated
with 1 lM concentration of doxorubicin. CIP2A level was measured using immu-
noblot analysis 24 h after the doxorubicin treatment.p53 proteins affected the doxorubicin-mediated up-regulation of
CIP2A expression (Fig. 4B). Next, HCT116 cells were transfected
with R273H, R249S, and R175H mutants. All mutant forms of
p53 partially blocked doxorubicin-mediated CIP2A down-regula-
tion (Fig. 4C). These ﬁndings imply that mutant p53 is able to act
as a dominant negative in doxorubicin-mediated CIP2A down-reg-
ulation in HCT116 cells. Therefore, wild type p53 seems to be nec-
essary but not sufﬁcient for the CIP2A down-regulation in response
to doxorubicin.
3.3. Akt is associated with regulation of CIP2A expression by
doxorubicin
To elucidate which signal pathway was involved in the doxoru-
bicin-mediated enhancement of CIP2A expression, p53-deﬁcient
HCT116 cells were pretreated with p38, JNK, MEK, or PI3K inhibi-
tors and then treated with doxorubicin 24 h. The p38 MAPK and
PI3K inhibitors blocked doxorubicin-induced CIP2A expression
(Fig. 5A). To further conﬁrm this, DN-PI3K, which mimics PI3KFig. 5. Analysis of the signal pathway involved in doxorubicin-induced CIP2A up-
regulation signal pathway. (A) The p53-deﬁcient HCT116 cells were pretreated with
various signal inhibitors, including 10 lM of SB203580, 20 lM of SP600125, 10 lM
of U0126, and 10 lM of LY294002, 30 min before doxorubicin treatment. CIP2A
level was measured using immunoblot analysis 24 h after the treatment of with
1 lM concentration of doxorubicin. (B) p53-deﬁcient HCT116 cells were transfected
with DN-PI3K or CA-PI3K, respectively, and treated with 1 lM concentration of
doxorubicin. CIP2A level was measured using immunoblot analysis 24 h after the
doxorubicin treatment. (C) HCT116 and p53-deﬁcient cells were treated with 0.25,
0.5, and 1 lM concentration of doxorubicin. Levels of Akt and phosphorylated Akt
were measured using immunoblot analysis 24 h after the doxorubicin treatment.
(D) HCT116 and p53-deﬁcient HCT116 cells were transfected with DN-Akt or CA-
Akt, respectively, and treated with 0.25, 0.5, and 1 lM concentration of doxorubicin.
CIP2A level was measured using immunoblot analysis 24 h after the doxorubicin
treatment.
Fig. 6. Effect of CIP2A on doxorubicin sensitivity in HCT116 and p53-deﬁcient
HCT116 cells. (A) CIP2A levels in HCT116 and p53-deﬁcient HCT116 cells were
measured using immunoblot analysis. (B) HCT116 and p53-deﬁcient HCT116 cells
were treated with 0.25, 0.5, 1, and 2 lM concentration of doxorubicin for 24 h, and
then viable cells were counted. (C) HCT116 cells were transfected with CIP2A
expression plasmid and then treated with 0.25, 0.5, 1, and 2 lM concentration of
doxorubicin for 24 h, and then viable cells were counted. Data shown are
representative of three independent experiments performed in triplicates. All
values are represented as the means ± standard deviation. ⁄P < 0.05.
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ined. DN-PI3K blocked doxorubicin-mediated increase in CIP2A
expression (Fig 5B). Because PI3K-activated Akt exerts an anti-
apoptotic activity through phosphorylation of substrates that
directly regulate the apoptotic pathway, such as Bad [17] and
caspase 9 [18], and doxorubicin regulates the phosphorylation
level of Akt in breast cancer cells [19], we assessed the phosphor-
ylation level of Akt after doxorubicin treatment. HCT116 cells
showed an increase in the level of Akt phosphorylation in response
to doxorubicin treatment, whereas p53-deﬁcient HCT116 cells
showed a decrease in Akt phosphorylation (Fig. 5C). Therefore,
we wondered whether Akt affected the level of CIP2A expression
in response to doxorubicin treatment. To this end, HCT116 cells
were transfected with DN-Akt to suppress doxorubicin-induced
Akt activation, and CIP2A expression was assessed. CIP2A expres-
sion was increased in HCT116 cells transfected with DN-Akt. When
p53-deﬁcient HCT116 cells were transfected with CA-Akt to acti-
vate doxorubicin-induced Akt suppression, CIP2A expression was
weakly suppressed (Fig. 5D). These results imply that Akt activa-
tion is associated with the doxorubicin-mediated regulation of
CIP2A expression.
To assess whether doxorubicin-mediated increase of CIP2A
expression in p53-deﬁcient HCT116 cells was related with resis-
tance to doxorubicin, ﬁrstly, levels of CIP2A expression in both cell
lines were compared. HCT116 cells showed higher CIP2A expres-
sion level than p53-deﬁcient HCT116 cells (Fig 6A). HCT116 cells
and p53-deﬁcient HCT116 cells were then treated with varying
concentrations of doxorubicin. Although HCT116 cells proliferated
faster than p53-deﬁcient HCT116 cells in the absence of doxorubi-
cin, the proliferation of p53-deﬁcient HCT116 cells was not rela-
tively decreased at the increasing concentration of doxorubicin
compared with HCT116 cells (Fig. 6B). In addition, HCT116 cells
in which CIP2A was overexpressed overcame the doxorubicin-
mediated inhibition of cell proliferation (Fig. 6C), indicating that
cells with an increase in CIP2A were more resistant to doxorubicin.4. Discussion
Cancers acquire resistance to chemotherapeutic drug. Although
a common feature of multidrug resistance is a net decrease in the
intracellular accumulation of drugs as a consequence of enhanced
drug efﬂux, other possible contributing mechanisms exist. For
example, alterations in glutathione metabolism [20,21], differen-
tial oxygen free-radical susceptibility [22], increased DNA repair,
and genetic alterations, including tumor-suppressor genes, onco-
genes, cell cycle regulator genes, and growth factor receptor genes,
are associated with drug resistance. The oncogene CIP2A is highly
expressed in human head and neck squamous cell carcinomas, co-
lon cancer, gastric cancer [4,23], and breast cancer tissues, and it is
involved in the clinical aggressiveness and malignant growth of tu-
mors [1]. However, the role of CIP2A in chemotherapeutic drug
resistance has not yet been established. We show here that the in-
crease in CIP2A expression is associated with doxorubicin sensitiv-
ity. Doxorubicin treatment decreased the expression of CIP2A in
cells having wild-type p53, including MCF-7 and HCT116 cells,
whereas it increased expression in cells having mutant p53, includ-
ing MDA-MB-231 and p53-deﬁcient HCT116 cells. Therefore, we
examined whether p53 was associated with the doxorubicin-
mediated regulation of CIP2A expression. Our results showed that
the doxorubicin-increased CIP2A expression was not regulated by
wild-type p53 (Fig 3B). However, mutant p53 blocked the doxoru-
bicin-mediated down-regulation of CIP2A expression in the pres-
ence of p53 (Fig 4C). It means that coexistence of mutant and
wild-type p53 is involved in the regulation of CIP2A expression
by the treatment of doxorubicin. Collectively, wild-type p53 is nec-
essary but not sufﬁcient for the suppression of CIP2A expression by
the treatment of doxorubicin.
In addition to a previous report showed that the depletion of
CIP2A inhibited cell growth and clonogenic capability regardless
of the presence of p53 [4], it is reported that CIP2A-positive and
p53-immunopositive patients show a shorter cumulative 10-year
overall survival rate than CIP2A-negative and p53-immunopositive
groups in gastric cancer [3]. Our result also provides that doxoru-
bicin-mediated increase of CIP2A expression in mutant p53-har-
boring tumor cells is associated with doxorubicin resistance,
whereas tumor cells expressing wild-type p53 are susceptible in
response to doxorubicin because of CIP2A down-regulation. In
addition, breast cancer patients with mutant p53 show a higher
expression level of CIP2A compared with patients with wild-type
p53 [1]. However, in our study, mutant p53 did not increase CIP2A
expression without doxorubicin treatment in vitro (Fig. 4A). There-
fore, further study on the regulation of CIP2A expression would
provide an answer about the relationship between p53 and CIP2A
expression and function in vivo.
Several reports have strongly suggested that Akt activation is
related to doxorubicin resistance. Depending on the cell types,
treatment of breast cancer cells with doxorubicin triggers a tran-
sient phosphorylation and activation or dephosphorylation and
inactivation of Akt through activation of PI3K [24], and the expres-
sion of upstream Akt activators, including HER2 and HER3, poten-
tiates Akt phosphorylation, and the resulting Akt activation leads
to drug resistance [25,26]. Because the expression of DN-Akt in
HCT116 cells and the expression of CA-Akt in p53-deﬁcient
HCT116 cells blocked the effect of doxorubicin on the differential
regulation of CIP2A expression (Fig. 5D), it is likely that Akt is in-
volved in the differential CIP2A expression in response to doxoru-
bicin treatment. In our system, HCT116 cells showed an increase in
Akt phosphorylation after doxorubicin treatment. HCT116 cells,
however, showed more sensitivity to doxorubicin-induced inhibi-
tion of cell proliferation than p53-deﬁcient HCT116 cells, which
showed Akt dephosphorylation in response to doxorubicin
760 Y.A. Choi et al. / FEBS Letters 585 (2011) 755–760treatment (Fig. 5C). HCT116 cells showed down-regulation of
CIP2A expression in response to doxorubicin treatment, and the
overexpression of CIP2A in HCT116 cells overcame the doxorubi-
cin-mediated inhibition of cell proliferation (Fig. 6B). These results
imply that CIP2A expression is a more critical event in doxorubicin
resistance than Akt phosphorylation.
It is known that doxorubicin-induced PI3K/Akt activation is
linked to p53 activation and that the resulting activated p53
stimulates target gene expression [27]. Although the doxorubi-
cin-PI3K-Akt-p53 pathway may regulate CIP2A expression, a
p53-independent doxorubicin-PI3K-Akt-CIP2A signal pathway
may exist because our data showed that the doxorubicin-regulated
CIP2A up-regulation was not completely dependent on wild-type
or mutant p53. It also remains to be elucidated how HCT116 cells
and p53-deﬁcient HCT116 cells show a differential Akt phosphor-
ylation pattern and CIP2A expression in response to doxorubicin
treatment. Our ﬁndings indicate that CIP2A inhibition is applicable
to developing combination chemotherapy of doxorubicin and that
p53 status is an important factor to be considered because mutant
p53 inhibits down-regulation of CIP2A expression in response to
doxorubicin.
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